These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 9313887)
1. Involvement of TNF-alpha secreting macrophages in lethal forms of human graft-versus-host disease. Facon T; Jouet JP; Noel-Walter MP; Bloget F; Bauters F; Janin A Bone Marrow Transplant; 1997 Sep; 20(6):511-5. PubMed ID: 9313887 [TBL] [Abstract][Full Text] [Related]
2. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation]. Lin Q; Dong M; Wang QM; Wen JY; Wu XY Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772 [TBL] [Abstract][Full Text] [Related]
4. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse. Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011 [TBL] [Abstract][Full Text] [Related]
5. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease. Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919 [TBL] [Abstract][Full Text] [Related]
6. A possible association between the presence of interleukin-4-secreting cells and a reduction in the risk of acute graft-versus-host disease. Takabayashi M; Kanamori H; Takasaki H; Yamaji S; Koharazawa H; Taguchi J; Tomita N; Fujimaki K; Fujisawa S; Maruta A; Ishigatsubo Y Exp Hematol; 2005 Feb; 33(2):251-7. PubMed ID: 15676220 [TBL] [Abstract][Full Text] [Related]
7. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659 [TBL] [Abstract][Full Text] [Related]
8. Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease. Marra DE; McKee PH; Nghiem P J Am Acad Dermatol; 2004 Oct; 51(4):543-6. PubMed ID: 15389188 [TBL] [Abstract][Full Text] [Related]
9. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers. Beksac M; Celebi H; Sargín D; Yalcin A; Topcuoglu P; Kalayoglu-Besisik S; Beyan C; Arslan O; Ozcan M; Gurman G; Ilhan O; Akan H Bone Marrow Transplant; 2003 May; 31(10):897-904. PubMed ID: 12748666 [TBL] [Abstract][Full Text] [Related]
10. Isolated testicular and bone relapse in children with acute myeloblastic leukemia and chronic graft versus host disease after allogeneic BMT. Yildirim I; Uçkan D; Cetin M; Tuncer M; Tezcan I Turk J Pediatr; 2007; 49(2):206-9. PubMed ID: 17907524 [TBL] [Abstract][Full Text] [Related]
11. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase. Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473 [TBL] [Abstract][Full Text] [Related]
12. Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion. Porter D; Levine JE Semin Hematol; 2006 Jan; 43(1):53-61. PubMed ID: 16412789 [TBL] [Abstract][Full Text] [Related]
13. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Matsue K; Tabayashi T; Yamada K; Takeuchi M Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146 [TBL] [Abstract][Full Text] [Related]
14. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético. Carreras E; Tomás JF; Sanz G; Iriondo A; Boqué C; López J; Cabrera R; Sureda A; de Soria VG; Sierra J; Sanz MA; Torres A Haematologica; 2000 May; 85(5):530-8. PubMed ID: 10800172 [TBL] [Abstract][Full Text] [Related]
15. Molecular remission induced by fractionated dose-escalating donor leukocyte infusion without graft-versus-host disease in a patient with chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation. Inai K; Wano Y; Yamamoto S; Ikebata Y; Iwasaki H; Tsutani H; Naiki H; Ueda T Anticancer Res; 1999; 19(6C):5631-4. PubMed ID: 10697631 [TBL] [Abstract][Full Text] [Related]
16. Dermatomyositis-like muscle pathology in patients with chronic graft-versus-host disease. Allen JA; Greenberg SA; Amato AA Muscle Nerve; 2009 Oct; 40(4):643-7. PubMed ID: 19670319 [TBL] [Abstract][Full Text] [Related]